David Steinberg
@DavidASteinberg
Followers
5K
Following
2K
Media
100
Statuses
4K
CBO Formation Bio. Serial biotech founder. Biotech, venture capital, pharma, science.
Boston
Joined August 2011
Excited to welcome our inaugural class of Entrepreneurs in Residence to @formationbio !.
Formation Bio welcomes our first class of Entrepreneurs in Residence! These dealmaking veterans will help drive pipeline growth, partnerships & BD strategy. Read more here:
1
0
1
We at @formationbio are thrilled to be working with Mikael on his post-Pfizer journey.
For his post-Pfizer era, Mikael Dolsten is already working with ~10 life science companies, ranging from large businesses to new startups. That includes Formation Bio, where he'll lead a drug-picking committee as an advisor. My latest at @endpts:
1
0
5
2/basically as good as a human analyst for that problem, with output in minutes vs days.
0
0
4
1/ Had an in depth brainstorm with GPT o1 that blew me away. Had to come up with metrics for team productivity - it took my parameters, came up with whole new ideas that balanced conflicting incentives, generated the formulae, then accurately modeled multiple nuanced scenarios.
1
0
3
RT @AndrewE_Dunn: “If we think about all the drug development activities, we think there’s a Muse for everything,” Formation Bio CEO Benjam….
0
7
0
RT @BenjamineYLiu: Meet Muse, our latest AI innovation for drug development—a tool designed to optimize patient recruitment built together….
0
15
0
RT @RectifyPharma: Welcome to our new Chief Business Officer, Bharat Reddy, Ph.D.! With deep business development expertise, Bharat’s leade….
0
2
0
RT @bebiopharma: The U.S. FDA has granted Orphan Drug Designation to BE-101, a novel engineered B Cell medicine (BCM) being developed for t….
0
2
0
Amazing milestone for B cells as protein factories. Congrats to the Be Bio team!!!.
Thrilled to announce the clearance of our IND from the FDA for BE-101 for the potential treatment of hemophilia B. We expect to initiate a Phase 1/2 study, BeCoMe-9, in the 2nd half of 2024. Full release here: #BCell #BeBold #BCellMedicines #BCMs
0
1
10
RT @bebiopharma: Thrilled to announce the clearance of our IND from the FDA for BE-101 for the potential treatment of hemophilia B. We expe….
0
4
0
RT @bebiopharma: Thrilled to announce new preclinical research demonstrating the production of active ALP by a BCM, which highlights BCMs a….
0
2
0
RT @LongwoodFund: A thoughtful write-up from the @BostonGlobe on the uniting power of #science, profiling repeat Longwood scientists and en….
0
5
0
RT @LongwoodLeaders: A special thank you to the amazing participants for phenomenal discussions and interactions at this year’s #longwo….
0
2
0
RT @LongwoodLeaders: Up now: @US_FDA Director Peter Marks & former Commissioner @SteveFDA join @LongwoodFund @drcwestphal for the #regula….
0
3
0
RT @LongwoodLeaders: Join #pharma R&D leaders Frank Nestle @sanofi and Jane Grogan @biogen in a fireside chat facilitated by @DavidASteinbe….
0
4
0
Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning.
Participating in the European Society of Gene & Cell Therapy 30th Annual Meeting in Brussels, the Be Bio research team will present data from two preclinical studies on engineered B cell medicines. Read more here #BeBio #ESGCT23 #BeBold
1
3
13
